Oral events related to low-dose methotrexate in rheumatoid arthritis patients

Brazilian Oral Research

Volumn 24, Issue 3, 2010, Pages 368-373

  Pedrazas, Carlos Henrique Silva ^a   de Azevedo, Mario Newton Leitão ^a   Torres, Sandra Regina ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Arthritis, rheumatoid; Methotrexate; Mucositis; Oral manifestations

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; MOUTH DISEASE; MOUTH MUCOSA; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MOUTH DISEASES; MOUTH MUCOSA; RISK FACTORS; SEX FACTORS;

EID: 77957946208     PISSN: 18068324     EISSN: 18073107     Source Type: Journal    
DOI: 10.1590/S1806-83242010000300018     Document Type: Article

References (27)

1. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am. 1994 May;20(2):513-28.
2. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003 Jun;48(6):1493-9.
3. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini, F et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004 Jul;50(7):2191-201.
4. Bailey KM, McDonagh JE, Prieur AM. Systemic juvenile idiopathic arthritis presenting in a young child with long term disability as an adolescent. Ann Rheum Dis. 2004 Dec;63(12):1544-8.
5. Carpenter EH, Plant MJ, Hassell AB, Shadforth MF, Fisher J, Clarke S, et al. Management of oral complications of disease-modifying drugs in rheumatoid arthritis. Br J Rheumatol. 1997 Apr;36(4):473-8.
6. Hoekstra M, van E de AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 May;62(5):423-6.
7. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999 Nov;159(21):2542-50.
8. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis. 2005 Feb;64(2):207-11.
9. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004 May;50(5):1370-82.
10. Chu EA, Allegra C. Antifolates. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. 2nd ed. Philadelphia: Lippincot-Raven; 1996. p. 109-47.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.
12. Torres SR. [Positive balance for the prevention campaingn in stomathology]. J ABORJ. 2003 Nov;60(1):24-5. Portuguese.
13. Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001 Jul;7(4):211-6.
14. Russell SL, Reisine S. Investigation of xerostomia in patients with rheumatoid arthritis. J Am Dent Assoc. 1998 Jun;129(6):733-9.
15. Torres SR, Paulo MT, Ruela SF, Corrêa FC, Oliveira TM, Uemoto L, et al. Análise quantitativa do fluxo salivar em pacientes com artrite reumatóide [resumo Pa280]. Braz Oral Res. 2004;18 Suppl:145.
16. Ramalho VL, Ramalho HJ, Cipullo JP, Burdmann EA. [Ciclosporine A-induced gingival hyperplasia]. Rev Assoc Med Bras. 2003 Apr-Jun;49(2):210-3. Portuguese.
17. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging. 2003 Oct;20(10):723-36.
18. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001 Aug;60(8):729-35.
19. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996 Dec;39(12):1951-60.
20. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002 Mar;4(4):266-73.
21. Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 2000 Oct;14(13):2065-74.
22. Tack DA, Rogers III RS. Oral Drug Reactions. Dermatol Ther. 2002 Sep;15(3):236-50.
23. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004 May;100 (9 Suppl):1995-2025.
24. Griffith SM, Fisher J, Clarke S, Montgomery B, Jones PW, Saklatvala J, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford). 2000 Oct;39(10):1102-9.
25. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis. 2004 Oct;63(10):1227-31.
26. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 2004 Apr;22(7):1268-75.
27. van E de AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002 Jun;41(6):658-65.